Alnylam

Press Releases

Mar 11,2019
Summary ToggleAlnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings
PDF Version
Mar 07,2019
Summary ToggleAlnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference
PDF Version
Mar 06,2019
Summary ToggleAlnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
PDF Version
Feb 28,2019
Summary ToggleAlnylam Announces Recipients of First Annual Advocacy for Impact Grants Program
PDF Version
Feb 07,2019
Summary ToggleAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity
PDF Version
Feb 06,2019
Summary ToggleAlnylam Announces Publication of Phase 1 Givosiran Data in The New England Journal of Medicine
PDF Version
Feb 04,2019
Summary ToggleAlnylam to Webcast Presentations at Upcoming February Investor Conferences
PDF Version
Jan 31,2019
Summary ToggleAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results
PDF Version
Jan 21,2019
Summary ToggleAlnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel
PDF Version
Jan 14,2019
Summary ToggleAlnylam Pharmaceuticals Prices Public Offering of Common Stock
PDF Version
Jan 14,2019
Summary ToggleAlnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock
PDF Version
Jan 07,2019
Summary ToggleAlnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates
PDF Version
Dec 28,2018
Summary ToggleAlnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference
PDF Version
Dec 10,2018
Summary ToggleAlnylam Announces Settlement of Litigation with Silence Therapeutics
PDF Version
Dec 06,2018
Summary ToggleAlnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day
PDF Version
Nov 29,2018
Summary ToggleAlnylam to Webcast R&D Day
PDF Version
Nov 26,2018
Summary ToggleVir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
PDF Version
Nov 21,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming Investor Conferences
PDF Version
Nov 09,2018
Summary ToggleAlnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
PDF Version
Nov 07,2018
Summary ToggleAlnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity
PDF Version
Displaying 1 - 20 of 1005 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More